BillionToOne (BLLN) vs CareDx (CDNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CareDx (CDNA) has outperformed BillionToOne (BLLN) over the past year, gaining 307.5% versus a loss of 18.3%. BillionToOne is the larger company by market cap ($4.30 billion vs $3.68 billion), about 1.2 times the size. On valuation, CareDx trades at a lower forward P/E (44.7x vs 57.3x for BillionToOne).
BillionToOne converts more of its revenue into profit, with a net margin of 2.4% versus -5.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLLN | CDNA |
|---|---|---|
| Share price | $89.92 | $70.00 |
| Market cap | $4.30B | $3.68B |
| 1-day change | -0.31% | -2.67% |
| YTD return | +9.87% | +271.55% |
| 1-year return | -18.25% | +307.45% |
| 5-year return | — | +65.21% |
| P/E ratio (TTM) | 97.74 | 29.54 |
| Forward P/E | 57.27 | 44.75 |
| EPS (TTM) | $0.92 | $2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $305.11M | $379.81M |
| Revenue growth (YoY) | +99.97% | +13.79% |
| Net income (latest FY) | $7.45M | $-21.35M |
| Gross margin | 68.32% | — |
| Operating margin | 5.25% | -8.10% |
| Net margin | 2.44% | -5.62% |
| 52-week high | $150.44 | $90.87 |
| 52-week low | $61.96 | $15.56 |
| Distance from 52-week high | -40.23% | -22.97% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +42.67% | +34.90% |
| Average volume | 639.36K | 1.30M |
| Shares outstanding | 43.27M | 52.54M |
| Employees | 713 | 761 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed BLLN by 325.7 percentage points over the past year.
- BillionToOne trades at a higher earnings multiple (97.7x vs 29.5x trailing P/E).
- BillionToOne is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -5.6 cents for CareDx.
- BillionToOne grew revenue faster in its latest fiscal year (+99.97% vs +13.79%).
About BillionToOne
BLLN stock →BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Health Care · Medical Specialities · 713 employees
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
BLLN vs CDNA FAQ
Which is bigger, BillionToOne or CareDx?
BillionToOne (BLLN) is larger, with a market capitalization of $4.30B compared with $3.68B for CareDx (CDNA).
Which stock has performed better over the past year, BLLN or CDNA?
CDNA returned +307.45% over the past 12 months, compared with -18.25% for BLLN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BLLN or CDNA?
CDNA has the lower trailing P/E at 29.5, versus 97.7 for BLLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BillionToOne and CareDx in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.